Muscle-Invasive Bladder Cancer Treatment Practices

Opinion
Video

Karine Tawagi, MD, and Sia Daneshmand, MD, offer comprehensive insights on treatment practices for patients with muscle-invasive bladder cancer.

Recent Videos
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Experts on bladder cancer
Related Content
The decision is backed by robust efficacy data from the phase 3 ENVISION trial, evaluating UGN-102 in patients with non-muscle invasive bladder cancer.

FDA Accepts New Drug Application for UGN-102 for Bladder Cancer

Roman Fabbricatore
October 16th 2024
Article

The decision is backed by robust efficacy data from the phase 3 ENVISION trial, evaluating UGN-102 in patients with non-muscle invasive bladder cancer.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Phase 3 EV-302 results supported the approval, showing a statically significant survival benefit compared with chemotherapy in urothelial carcinoma.

Enfortumab Vedotin Combo Earns Japanese Approval for Urothelial Carcinoma

Roman Fabbricatore
September 24th 2024
Article

Phase 3 EV-302 results supported the approval, showing a statically significant survival benefit compared with chemotherapy in urothelial carcinoma.

Emerging Immunotherapy Approaches For Urothelial Cancer

Emerging Immunotherapy Approaches For Urothelial Cancer

Petros Grivas, MD, PhD
February 4th 2019
Podcast

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

Neoadjuvant Durvalumab/Chemo, Adjuvant Durvalumab Improves EFS in Cisplatin-Eligible MIBC

Neoadjuvant Durvalumab/Chemo, Adjuvant Durvalumab Improves EFS in Cisplatin-Eligible MIBC

Courtney Flaherty
September 15th 2024
Article

Thomas Powles, MBBS, MRCP, MD, presented results from the NIAGRA trial assessing perioperative durvalumab in patients with cisplatin-eligible MIBC.

Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.

Durvalumab Shows Improvement in EFS/OS for Muscle-Invasive Bladder Cancer

Roman Fabbricatore
June 25th 2024
Article

Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.